MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Novo Nordisk
Biotech

Novo drops oncology ambitions, early-stage MASH prospects

The Danish pharma is winding down a range of early-stage programs for liver disease, oncology and stem cells.
James Waldron Nov 5, 2025 7:21am
cartoon of man unplugging from outlet

Pfizer pulls the plug on 11 programs

Nov 4, 2025 2:40pm
ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin
Favicon Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am
Graphic of two hands shaking under a red and purple light

Novo inks $4.7B Akero buyout to bag late-phase MASH prospect

Oct 9, 2025 8:21am
three triple doors opportunity cracked open ajar

89bio was left between a Roche and a hard place in buyout talks

Oct 2, 2025 9:55am
liver

Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug

Sep 18, 2025 5:02am